Sign in
Active, not recruitingNo phase

COMPASSION S3 Post-Approval Study

Key facts

Who runs it
Edwards Lifesciences
Where
Aurora, Austin, Birmingham, Boston, Charlottesville, Cincinnati, Columbus, Dallas, Durham, Los Angeles, Minneapolis, New York, Newark, Oak Lawn, Philadelphia, Pittsburgh, Salt Lake City, and St Louis, United StatesSee the 19 sites
Trial code
Status
Active, not recruiting
People taking part
150 people enrolled
Started
13 Apr 2021
Expected to end
Aug 2030
Type of study
Observational
Treatments tested
  • SAPIEN 3 THV
Record updated
3 February 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Dysfunctional RVOT conduit or previously implanted surgical valve
  • RVOT/PV with ≥ moderate regurgitation and/or a mean RVOT/PV gradient of ≥ 35 mmHg

Who cannot take part

  • Active bacterial endocarditis or other active infections
  • Inability to tolerate an anticoagulation/antiplatelet regimen

Where in United States

  • Children's Hospital of ColoradoAurora, United States
  • Dell Children'sAustin, United States
  • University of AlabamaBirmingham, United States
  • Boston Children's HospitalBoston, United States
  • University of VirginiaCharlottesville, United States
  • Cincinatti Children's HospitalCincinnati, United States
  • Nationwide Children's HospitalColumbus, United States
  • Children's Health DallasDallas, United States
  • Duke UniversityDurham, United States
  • Cedars SinaiLos Angeles, United States
  • Minneapolis HeartMinneapolis, United States
  • Columbia University Medical Center/NYPHNew York, United States
  • Mount SinaiNew York, United States
  • Newark Beth Israel Medical CenterNewark, United States
  • Advocate Childrens HospitalOak Lawn, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • University of Pittsburgh Medical CenterPittsburgh, United States
  • Primary Children'sSalt Lake City, United States
  • St. Louis Children's HospitalSt Louis, United States

About the trial

What the trial wants to find out

This study will monitor device performance and outcomes of the SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention.

The group in the trial

  • TPVR

    Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).

    Treatment: SAPIEN 3 THV

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional THV Post-Approval Study
Record updated
3 February 2026